Significant agreements (Tables)

12 Months Ended

Dec. 31, 2021

Significant agreements.

Summary of revenue recognized from collaboration arrangements

	Year Ended
	December 31,
	2021		2020		2019
Collaboration revenues
Ionis	$	4,242	$	—	$	—
Genentech		5,660		4,896		—
Dementia Discovery Fund		391		436		394
Sanofi		—		—		10,724
AstraZeneca		1,404		2,696		1,683
Oxurion		—		2,362		—
Material Transfer Agreement		—		—		1,000
Total collaboration revenues	$	11,697	$	10,390	$	13,801

Summary of performance obligations

	Allocation of
Performance Obligations	Transaction Price
Combined licenses and research and discovery performance obligation	$	34,100
Four material rights associated with credits for IND Acceptance fees		3,900
	$	38,000

Summary of changes in the balances of the Company's contract assets and liabilities

The following table presents changes in the balances of the Company’s contract assets and liabilities (in thousands):

	Beginning Balance						Impact of		Ending Balance
	January 1,						Exchange		December 31,
	2021		Additions		Deductions		Rates		2021
Contract liabilities:
Deferred revenue
Ionis collaboration deferred revenue	$	3,000	$	36,002	$	(4,242)	$	(645)	$	34,115
Genentech collaboration deferred revenue		27,579		13,000		(5,660)		(483)		34,436
DDF collaboration deferred revenue		821		—		(391)		(2)		428
AstraZeneca collaboration deferred revenue		3,756		54		(1,404)		(45)		2,361
Total deferred revenue	$	35,156	$	49,056	$	(11,697)	$	(1,175)	$	71,340

	Beginning Balance						Impact of		Ending Balance
	January 1,						Exchange		December 30,
	2020		Additions		Deductions		Rates		2020
Contract liabilities:
Deferred revenue
Ionis evaluation and option agreement deferred revenue	$	—	$	3,000	$	—	$	—	$	3,000
Genentech collaboration deferred revenue		—		31,000		(4,896)		1,475		27,579
DDF collaboration deferred revenue		744		500		(436)		13		821
AstraZeneca collaboration deferred revenue		4,913		585		(2,696)		954		3,756
Total deferred revenue	$	5,657	$	35,085	$	(8,028)	$	2,442	$	35,156

Summary of recognition of revenues as a result of changes in contract asset and contract liability balances

During the years ended December 31, 2021, 2020 and 2019, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods (in thousands):

	Year Ended
	December 31,
	2021		2020		2019
Revenue recognized in the period from:
Revenue recognized based on proportional performance	$	9,652	$	6,326	$	429
Revenue recognized based on expiration of material rights		1,876		1,702		9,984
Revenue recognized based on changes in transaction price		169		—		—
Total	$	11,697	$	8,028	$	10,413

Genentech

Significant agreements.

Summary of allocation of transaction price to separate performance obligations

	Allocation of
Performance Obligations	Transaction Price
Genentech Collaboration Program #1 Performance Obligation	$	4,019
Genentech Collaboration Program #2 Performance Obligation		8,037
Specified Targeting Arm Material Right Arm for Genentech Collaboration Program #1		352
Two material rights associated with the LSR Go Option for Collaboration Programs #1 and #2		12,400
Material rights associated with limited substitution rights		1,187
Two material rights for Expansion Options		7,005
	$	33,000

AstraZeneca

Significant agreements.

Summary of allocation of transaction price to separate performance obligations

	Allocation of
Performance Obligations	Transaction Price
Target Three Research License and Related Services	$	650
Target 3 Material Right		1,504
Target 4 Material Right		1,204
Target 5 Material Right		1,165
Target 6 Material Right		1,127
	$	5,650